Modigh K
Department II, S:t Jörgen Hospital, Göteborg, Sweden.
Acta Psychiatr Scand Suppl. 1987;335:57-74. doi: 10.1111/j.1600-0447.1987.tb07749.x.
The efficacy of tricyclic antidepressants and monoamine oxidase inhibitors (MAOI) in the treatment of panic syndromes (panic disorder and agoraphobia with panic attacks) and obsessive-compulsive disorders is reviewed. Imipramine has been reported as significantly more effective against panic attacks than placebo or other psychoactive drugs in 12 of 16 studies. Clomipramine has been found superior to placebo or other psychoactive drugs in 5 controlled studies. The effectiveness of these drugs is also reflected in a large number of open trials. The MAOI phenelzine has been reported to be effective in 5 controlled studies. Clomipramine is the best documented drug in the treatment of obsessive-compulsive disorders. Its effectiveness has been documented in 7 controlled studies. Most investigators consider the effects in panic syndromes as well as in obsessive-compulsive disorders to be unrelated to the antidepressant effect.
本文综述了三环类抗抑郁药和单胺氧化酶抑制剂（MAOI）在治疗惊恐综合征（惊恐障碍和伴有惊恐发作的广场恐惧症）及强迫症方面的疗效。在16项研究中的12项里，有报告称丙咪嗪在对抗惊恐发作方面比安慰剂或其他精神活性药物显著更有效。在5项对照研究中，发现氯米帕明优于安慰剂或其他精神活性药物。这些药物的有效性在大量开放性试验中也有所体现。有报告称MAOI苯乙肼在5项对照研究中有效。氯米帕明是治疗强迫症方面记录最详实的药物。其有效性在7项对照研究中得到了证实。大多数研究者认为其在惊恐综合征和强迫症方面的效果与抗抑郁作用无关。
